Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Vaccine Maker JGAD Completes Reverse Merger with China Bio-Immunity

publication date: Aug 7, 2008

Dalian Jingang-Andi Bio-Products Co. Ltd., whose products are sold under the brand name “JGAD,” completed a reverse merger with China Bio-Immunity Corporation. JGAD is a vaccine maker that derives the majority of its revenue from a rabies vaccine. In exchange for 13,246,697 shares of China Bio-Immunity’s stock, all of JGAD was transferred into China Bio-Immunity. The $9.50 share price of China Bio-Immunity gives the newly reconstituted company a market capitalization of $158 million. More details...

Stock Symbol: (OTCBB: CHHB)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here